Sorafenib effective in patients with non-small cell lung cancer, but low survival rates reported

January 10, 2012

Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory," according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine, held Jan. 8-11, 2012.

Patients with lung cancer and a KRAS mutation are believed to have a and may not benefit from treatment with epidermal growth factor receptor , according to study author Wouter W. Mellema, M.D., a doctoral candidate at VU University Medical Center in Amsterdam.

"There is a great need for targeted treatment options for patients with non-small cell lung cancer () with a KRAS mutation," he said.

In the phase 2, multicenter study conducted in the Netherlands, researchers assigned 57 patients with NSCLC and a KRAS mutation to 400 mg of sorafenib twice daily.

At six weeks, Mellema and colleagues reported a rate of no progression of 52.6 percent. Fifteen patients stopped treatment before six weeks — 10 of whom stopped due to clinical progression. Median progression-free survival was 2.3 months, and median overall survival was 5.3 months. The researchers reported that 14 patients are still alive.

"Sorafenib could be a useful drug in this patient population by inhibiting the growth-stimulating signal of the RAS protein," Mellema said. "However, although showed relevant activity, the outcome was unsatisfactory."

Mellema and his team had conducted a pilot study in 10 patients, which showed "very promising results. Unfortunately, the results of the phase 2 study were less optimistic. We expected that progression-free survival and overall survival would be better [in the phase 2 study]," Mellema said.

He suggested that the KRAS mutation causes early progression by stimulating cell growth through an alternative pathway. "Future studies currently in preparation in our group should focus on simultaneous inhibition of these pathways," he said.

Explore further: EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy

Related Stories

EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy

July 5, 2011
In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the ...

Antifolates show promise against NSCLC subtype

November 14, 2011
Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer ...

Genetic composition of multicentric lung tumors appears to be similar

January 9, 2012
Multicentric carcinogenesis with the same genetic mutation appears to occur in lung adenocarcinoma, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and ...

Recommended for you

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

How CD44s gives brain cancer a survival advantage

July 19, 2017
Understanding the mechanisms that give cancer cells the ability to survive and grow opens the possibility of developing improved treatments to control or cure the disease. In the case of glioblastoma multiforme, the deadliest ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.